Bristol-Myers Squibb (BMY) Completes Inhibitex (INHX) Acquisition

Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. (Nasdaq: INHX) at a purchase price of $26.00 per share. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on February 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Two Harbors receives final approval for CrossCountry Mortgage merger
• loanDepot receives NYSE non-compliance notice over stock price